Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard L Wasserman

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Allergy and Asthma Proceedings|December 21, 2006
Real-world assessment of a metered-dose inhaler with integrated dose counterRichard L Wasserman, Ketan Sheth, William R Lincourt, et al.
Journal of Clinical Immunology|July 18, 2017
Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary ImmunodeficiencyRichard L Wasserman, Isaac R Melamed, Mark R Stein, et al.
Journal of Clinical Immunology|March 20, 2017
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex<sup>®</sup> 10% Versus Gammaplex<sup>®</sup> 5% in Subjects with Primary ImmunodeficiencyRichard L Wasserman, Isaac R Melamed, Mark R Stein, et al.
Immunotherapy|December 21, 2021
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseasesRichard L Wasserman, Sudhir Gupta, Mark Stein, et al.
Clinical Immunology (Orlando, Fla.)|January 14, 2014
Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency diseaseStephen Jolles, Michael Borte, Robert P Nelson, et al.
Journal of Agricultural and Food Chemistry|June 14, 2014
Decreased immunoglobulin E (IgE) binding to cashew allergens following sodium sulfite treatment and heatingChristopher P Mattison, Wendy A Desormeaux, Richard L Wasserman, et al.
Allergy and Asthma Proceedings|October 3, 2012
C1-inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health-related quality of lifeAgaindra K Bewtra, Robyn J Levy, Kraig W Jacobson, et al.
Journal of Clinical Immunology|September 25, 2008
Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficienciesMark R Stein, Robert P Nelson, Joseph A Church, et al.
Toxicology Reports|September 30, 2017
Heat-induced alterations in cashew allergen solubility and IgE bindingChristopher P Mattison, Yvette Bren-Mattison, Barry Vant-Hull, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 4, 2009
Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiencyRichard L Wasserman, Joseph A Church, Hans H Peter, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Allergy and Asthma Proceedings|December 21, 2006
Real-world assessment of a metered-dose inhaler with integrated dose counterRichard L Wasserman, Ketan Sheth, William R Lincourt, et al.
Journal of Clinical Immunology|July 18, 2017
Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary ImmunodeficiencyRichard L Wasserman, Isaac R Melamed, Mark R Stein, et al.
Journal of Clinical Immunology|March 20, 2017
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex<sup>®</sup> 10% Versus Gammaplex<sup>®</sup> 5% in Subjects with Primary ImmunodeficiencyRichard L Wasserman, Isaac R Melamed, Mark R Stein, et al.
Immunotherapy|December 21, 2021
Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseasesRichard L Wasserman, Sudhir Gupta, Mark Stein, et al.
Clinical Immunology (Orlando, Fla.)|January 14, 2014
Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency diseaseStephen Jolles, Michael Borte, Robert P Nelson, et al.
Journal of Agricultural and Food Chemistry|June 14, 2014
Decreased immunoglobulin E (IgE) binding to cashew allergens following sodium sulfite treatment and heatingChristopher P Mattison, Wendy A Desormeaux, Richard L Wasserman, et al.
Allergy and Asthma Proceedings|October 3, 2012
C1-inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health-related quality of lifeAgaindra K Bewtra, Robyn J Levy, Kraig W Jacobson, et al.
Journal of Clinical Immunology|September 25, 2008
Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficienciesMark R Stein, Robert P Nelson, Joseph A Church, et al.
Toxicology Reports|September 30, 2017
Heat-induced alterations in cashew allergen solubility and IgE bindingChristopher P Mattison, Yvette Bren-Mattison, Barry Vant-Hull, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 4, 2009
Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiencyRichard L Wasserman, Joseph A Church, Hans H Peter, et al.
Pageof 10